← Back to Search

Other

Corticosteroid Injection vs. Shock Wave Therapy for Tennis Elbow

Phase 4
Waitlist Available
Led By Scott M Tintle, MD
Research Sponsored by Walter Reed National Military Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of lateral epicondylitis based on primary complaint of lateral elbow pain and either tenderness over the lateral epicondyle with direct palpation, or exacerbation of pain at the lateral elbow with resisted dorsiflexion of the wrist
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will compare the effects of two different treatments for chronic lateral epicondylitis (tennis elbow) on pain and function.

Who is the study for?
This trial is for adults with chronic tennis elbow who haven't improved after at least 4 weeks of non-surgical treatments like rest, anti-inflammatory drugs, or physical therapy. It's not for those under 18, pregnant women, patients who've had steroids in the last 3 months, or individuals with certain allergies and other pain syndromes.Check my eligibility
What is being tested?
The study compares two treatments for chronic tennis elbow: corticosteroid injections (Kenalog and lidocaine) versus high energy extracorporeal shock wave therapy (ESWT). The goal is to see which treatment better improves pain and function.See study design
What are the potential side effects?
Corticosteroid injections may cause pain at the injection site, skin discoloration, and weakening of nearby tendons. ESWT might lead to temporary redness, swelling, bruising or numbness around the treated area.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with tennis elbow due to pain and tenderness on the outer part of my elbow.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hand
Mayo Elbow Score
Patient-Related Tennis Elbow Evaluation (PRTEE)
+2 more
Secondary outcome measures
Grip Strength

Trial Design

2Treatment groups
Active Control
Group I: Kenalog (triamcinolone )Active Control2 Interventions
Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
Group II: extracorporeal shock wave therapyActive Control1 Intervention
Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.

Find a Location

Who is running the clinical trial?

Walter Reed National Military Medical CenterLead Sponsor
136 Previous Clinical Trials
37,255 Total Patients Enrolled
Scott M Tintle, MDPrincipal InvestigatorWRNMMC Orthopaedics

Media Library

Extracorporeal Shock Wave Therapy (Other) Clinical Trial Eligibility Overview. Trial Name: NCT02613455 — Phase 4
Tennis Elbow Research Study Groups: Kenalog (triamcinolone ), extracorporeal shock wave therapy
Tennis Elbow Clinical Trial 2023: Extracorporeal Shock Wave Therapy Highlights & Side Effects. Trial Name: NCT02613455 — Phase 4
Extracorporeal Shock Wave Therapy (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02613455 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential hazards may arise from administering Kenalog (triamcinolone) to patients?

"The safety of Kenalog (triamcinolone) is rated 3 out of 3 since it has undergone Phase 4 trials and been approved for medical practice."

Answered by AI

How many participants are in the study group of this clinical trial?

"At this time, there are no more openings for participation in this trial. It was initially published on July 1st of 2015 and last edited in November 23rd of the same year. If you're looking to join another study, lateral epicondylitis has 23 active trials while Kenalog (triamcinolone) has 155 open studies currently accepting patients."

Answered by AI

Could you please elucidate the past clinical research that has been conducted with Kenalog (triamcinolone)?

"Presently, 155 clinical trials examining Kenalog (triamcinolone) are underway. Of those studies, 39 have advanced to the 3rd phase of research. Although Chonqqing is home to most of these experiments, 1164 locations across the world are running tests with this medication."

Answered by AI

Are any additional volunteers needed for this medical trial?

"A glance at clinicaltrials.gov reveals that this trial is not accepting any more participants, as it was first posted on July 1st 2015 and last updated November 23rd of the same year. However, there are 178 other medical trials actively recruiting patients right now."

Answered by AI

What conditions is Kenalog (triamcinolone) commonly prescribed to treat?

"Kenalog (triamcinolone) has been demonstrated to have therapeutic value for treating minor burns, ulcerative colitis, and organ transplantation."

Answered by AI
~8 spots leftby Mar 2025